 |
|
|
|
 |
 |
 |
Indian Chemical
Industry Shows Great Potential
A growing Indian economy, particularly in
the increasing manufacturing sector, will
continue to drive the growth of the
country's chemical industry for the next
decade. A sharp rise in per capita income
will also be a factor. Since 2006, the
Indian chemical industry as grown at 12
percent per year, and that rate could
increase to as much as 16 percent annually
by 2010. Pharmaceuticals and biotechnology
are leading the way with growth rates of 18
percent per year. With a 14 percent annual
growth rate, the petrochemical sector is
also receiving significant investment
dollars. In 2007, the government announced
its plans for investing more than $9 billion
over the next five years and a policy to
create several designated petroleum,
chemicals, and petchem investment regions (PCPIR)
throughout the country. Analysts expect
India to become a major global player in
specialties and polymers, in addition to
pharma, biotech and petrochemicals. Rising
feedstock costs, reduced credit availability
and shortages of skilled engineers and
construction equipment could, however, delay
projects planned for the near future.
|
 |
 |
 |
 |
 |
 |

|
 |
 |
 |
|
|
 |
 |
 |
Dr. Reddy's Makes
Western Acquisitions

Dow Chemical announced that it is selling
its Chirotech Technology Ltd. business to
Dr. Reddy's Laboratories Ltd. for an
undisclosed amount. The deal is expected to
be completed by the end of April 2008. With
the acquisition, Dr. Reddy's gains access to
proprietary chiral and biocatalysis
technology, as well as scale-up capability,
and it will get a stronger position in the
industrial synthesis of complex
prostaglandins and carbohydrate chemistry.
With the sale, Dow will be able to focus
more on core markets, an arena where it can
become a long-time leader.
Separately, BASF agreed to sell a U.S.-based
drug production facility and its related
contract manufacturing business to Dr.
Reddy's Laboratories. The plant makes and
packages prescription and over-the-counter
products. According to BASF, the facility
was sold because it is not part of the
company's core businesses, which include
APIs, excipients and custom synthesis
services.
Other Indian firms are looking for
acquisitions in the United States and
Europe. Biotech companies, such as GVK
Biosciences, TCG Life Sciences, Jubilant
Organosys, Sanmar Speciality Chemicals
Limited and Syngene, offer contract research
and manufacturing services to the life
science industries, and hope to add custom
synthesis assets in both regions to their
portfolios. Acquisitions provide not only
existing infrastructure and expertise, but
an established customer base on which to
build.
|
 |
 |
 |
 |
 |
 |

|
 |
 |
 |
|
|
 |
 |
 |
FDA Faces Further
Criticisms on International Inspections
The Government Accountability Office (GAO)
testified before Congress that despite the
FDA's increased oversight of foreign drug
facilities to about 11 percent, the agency
still needs around $70 million to inspect
adequaltely all overseas manufacturing
operations. FDA head Andrew von Eschenbach
said that a complete overhaul of the system
was required, not just an increase in
overseas inspections. The FDA has already
set in motion its plan to place agents in
China and other countries.
Separately, Democrats in the House of
Representatives have proposed legislation,
the "FDA Globalization Act," which would
require the labeling of all foods, drugs and
medical devices with country of origin
information. Drug labels would include a
listing of the origin of active ingredients
and the place of manufacture. The
legislation would also create a permanent
inspection force dedicated to inspecting
facilities in foreign countries. Funds to
support these activities would be provided
through higher registration and user fees.
Janet Woodcock, director of the FDA's Center
for Drug Evaluation and Research, said the
agency should be allowed to set inspection
schedules based on risk assessments, and
that the inspection requirement in the
legislation might be a financial burden to
the FDA. She did not support the immediate
imposition of higher fees.
The FDA has announced, though, that it will
hire 1,300 additional scientists by October
2008 to monitor drug-safety data before and
after product approval and to manage the
safety and inspections of imported goods.
|
 |
 |
 |
 |
 |
 |

|
 |
 |
 |
|
|
|
|
|
|
|
|
|
| | |